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Introduction
Assessment of the QT interval started to receive increased
regulatory attention in the late 1980s.
The heightened safety concern was precipitated by
repeated reports on torsade de pointes (TdP) and other
arrhythmias occurring in patients treated with an antihis-
tamine drug (terfenadine) [1]. ECG measurements per-
formed during the clinical development process by
cardiologists (allegedly using "eyeball/calliper" tech-
niques), have failed to identify drug-related QT prolonga-
tion. The false-negative conclusions consequently
provided have resulted in a number of serious adverse
events and, ultimately in the removal of terfenadine from
the US market [2].
Similarly, in early 1990s, attempts to decrease sudden car-
diac death by novel antiarrhythmic drugs (Cardiac
Arrhythmia Suppression Trial – CAST), have demon-
strated that a certain degree of arrhythmia suppression
was paralleled by a proarrhythmic effect, translated in 3-
fold increase in mortality rate among patients treated with
encainide or flecainide [3].
Awareness about the potential risk of drug-induced QT
prolongation and subsequent risk of malignant arrhyth-
mias has increased gradually since then and, particularly
during the past years, regulatory requirements for short-
and long-term safety of any new chemical entities have
become more stringent. For example, after CAST, the FDA
changed its advice regarding antiarrhythmic drugs and
required evidence showing minimally, that a new
antiarrhythmic agent did not cause death in patients.
The first regulatory guidelines regarding clinical evalua-
tion of the QT/QTc interval prolongation in the context of
new drug development were issued in 1997 by the Com-
mittee for Proprietary Medicinal Products (CPMP) [4].
Most recently, the FDA has issued its 4th draft document
on the matter, clarifying the specific safety issues related to
QT/QTc prolongation [5].
Congenital Long QT Syndrome
The frequency of congenital long QT syndrome (LQTS) is
unknown, but appears to be a common cause of sudden
and unexplained death in children and young adults. It is
much more common than previously thought – possibly
as frequent as 1 in 5,000, and may cause 3,000 – 4,000
sudden deaths in children and young adults each year in
US [6]. It is present in all races and all ethnic groups, but
it is not certain if the frequency is the same in all races.
Clinically, the diagnosis of LQTS is suggested by the
occurrence of syncope, cardiac arrest or sudden death [7].
The diagnosis is established on the basis of prolonged QT
interval on the ECG. A clearly prolonged QT interval is
present in 60% to 70% of affected persons, but the QT is
normal or only borderline prolonged in 30–40% of those
affected. Overall, about 12% of LQTS patients have a nor-
mal QT interval on their baseline, resting ECG.
Torsade de pointes (TdP) tends to appear during exercise
(especially swimming) or psychological stress in LQT1,
during stress or startle (particularly auditory stimuli) in
LQT2 and during rest in LQT3 [8]. Studies on transmural
dispersion of repolarization (TDR) in experimental mod-
els have shown it to be linked to the genesis of TdP. TDR
Published: 03 February 2005
Current Controlled Trials in Cardiovascular Medicine 2005, 6:1 doi:10.1186/1468-6708-6-1
Received: 22 November 2004
Accepted: 03 February 2005
This article is available from: http://cvm.controlled-trials.com/content/6/1/1
© 2005 Pater; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Current Controlled Trials in Cardiovascular Medicine 2005, 6:1 http://cvm.controlled-trials.com/content/6/1/1
Page 2 of 13
(page number not for citation purposes)
has different features in the three different forms of LQT
referenced as LQT1, LQT2 and LQT3 [9].
Diurnal and sex-related pattern of QT interval
The maximal QT interval over 24 hours in normal subjects
is longer than thought so far (440 ms). Both QT and QTc
intervals are longer during sleep. The QT interval and QTc
variability reach peak shortly after awakening, which may
reflect increased autonomic instability during early wak-
ing hours. The time of the peak value corresponds to the
period of reported increased vulnerability to ventricular
tachycardia and sudden cardiac death. These findings
have implications regarding the definition of QT prolon-
gation and its use in predicting arrhythmias and sudden
death [10].
At rest, the surface ECG in women displays longer QT
interval [11], lower T wave amplitude [12] and less QT
dispersion [13]. The QT interval displays greater shorten-
ing during exercise as compared to men, as a consequence
[14]. Women are also known to have a greater propensity
towards developing TdP when treated with agents belong-
ing to class III antiarrhythmic drugs [15,16]. Besides,
women are more susceptible to development of malig-
nant arrhythmias in various settings of QT prolongation
[12]. The basis for sex differences in repolarization appear
to be, at least in part, influenced by sex hormones [17].
However, most recent data derived from a novel, auto-
mated QT-analysis algorithm, indicate that there are also
sex differences in the dynamics of the QT interval during
exercise and recovery in healthy subjects [18]. Women
exhibited greater QT-interval shortening during accelerat-
ing heart rates and greater QT-interval prolongation dur-
ing decelerating heart rates than in men. These results
suggest that women might have a greater QT interval-rate
adaptation, contributing to the greater prevalence of drug-
induced TdP episodes in women as compared to men.
In this context, the currently 20 ms sex difference in the
rate-adjusted QT interval, recommended by the regulatory
agencies, might need to be revised.
Acquired forms of Long QT interval in diseased patients
It is estimated that more than 50 marketed agents and an
equivalent number of drugs under development have
been found to block potassium channels, to prolong the
QT interval and induce, in some individuals, malignant
arrhythmias. TdP is, however, a relatively rare event with
a rate of 2–3% for some drugs [19]. Drugs which prolong
the QT interval exist in every therapeutic class [20]. An
international registry for cases of drug-induced arrhyth-
mias associated with QT prolongation can be found on
the web [21].
The pathophysiology of the TdP
Prolongation of the QT interval on the ECG is caused by
increased duration of the action potential (AP) of the ven-
tricular myocytes. Inhibition or activation of the potas-
sium channels in the cells belonging to the different
myocardial layers (Purkinje cells, subendocardial myo-
cytes, mid-myocardial M cells and subepicardial myo-
cytes) [22], interferes with the normal repolarization
process and triggers different patterns of AP duration. The
M cells for example, are characterised by prolonged repo-
larization in comparison with the epicardial or the endo-
cardial layers.
The potassium channels are of particular importance in
drug-related QT changes, most notably the rapid compo-
nent of the delayed rectifier potassium current (IKr) chan-
nel. Blockage of the channel caused by the human ether-
a-go-go-related gene (HERG) protein, the gene encoding
for the IKr, has been implicated in many of the drug-
induced changes.
The model used to explain the increased propensity
toward malignant arrhythmias secondary to prolonged
QT interval is based on extraneously induced, altered
depolarization process with occurrence of "early after-
depolarization" action potentials (EADs), which register
on the surface ECG as prolonged QT interval [23].
In the drug-induced model, any drug, normally used for
therapeutic purposes, but which interferes with the
inward/outward ion currents across the cell membrane is
leading to a prolongation of the action potential duration
(APD) and thereby delayed repolarization. Certain drugs
have the property to block the potassium channels (IKr) in
order to achieve a desired antiarrhythmic effect. These
types of changes facilitate additional inward Ca++ currents
that further prolong the action potential. Consequently,
the AP not only fails to repolarize but also depolarizes
again, creating characteristics "humps" which, actually are
EADs (Fig. 1A) [24].
Genetic defects of the Na+ or of the K+ channels lead to
lengthening of QT interval and EADs which may trigger
ventricular extrasystoles (VES). Occurrence of burst-like,
repetitive EADs may degenerate in a tachycardia (see Fig.
1B) with particular features, termed torsade de pointes
[25]. The French term torsade de pointes, suggests a rapid
polymorphic tachycardia in which the QRS axis rotates
360 degrees over a sequence of 5 to 20 complexes [15].
Such early EADs also occur in a multitude of cases such as:
bradycardia, diuretic-induced hypokalemia or hypomag-
nesemia, treatment with natrium or calcium channel
blockers.Current Controlled Trials in Cardiovascular Medicine 2005, 6:1 http://cvm.controlled-trials.com/content/6/1/1
Page 3 of 13
(page number not for citation purposes)
Preferential prolongation of the action potential duration
in the M cells is thought to underlie QT prolongation, the
phenotypic appearance of abnormal T-waves, the patho-
logic U-wave, and the development of TdP.
It is generally accepted that a focal activity initiates the
onset of TdP, whereas functional re-entry is responsible
for its maintenance [26].
Results from more recent research (27) suggest that
changes in a new variable termed "T-wave peak to T-wave
end" interval (TPE) would predict increased risk in sub-
jects with LQT1 and LQT2. These changes would reflect
the dynamicity of the transmural dispersion of repolariza-
tion (TDR) in clinical setting, in LQTS patients. Increased
TPE interval may show to be the electrophysiological sub-
strate for TdP. Modulation of the TPE interval magnitude
seems to be a property of the Iks and Ikr (rapidly respec-
tively slowly activating delayed rectifier potassium cur-
rent) defects. The TPE interval, as an index of TDR, has
been proved to be clinically useful in assessing arrhythmic
risk [28-31].
Current regulatory recommendations. 
Objectives and Scope
Drugs with significant effects on repolarization must be
identified and their risk quantified in preclinical and clin-
ical development. Risk-benefit assessment of drugs under
development, with particular emphasis to their propen-
sity to prolong repolarization should be individualized to
their pharmacokinetic and pharmacodynamic profile as
well as to their safety characteristics. The following major
aspects need to be addressed:
• Rigorous assessment of the agent's effects on the QT/
QTc interval.
• Assessment of the QT/QTc prolongation-related safety
risks of the particular drug against its potential benefits.
The above-mentioned issues should be taken into account
in any of the following circumstances:
• Development of a novel agent (with non-antiarrhythmic
properties).
• A marketed agent for which new dose or route is being
developed (with consequent potential increases in phar-
macokinetic parameters – Cmax, AUC values).
• A marketed agent for which a new indication or new tar-
get patient population is pursued.
• A marketed agent belonging to a chemical or pharmaco-
logical class in which any other drug may have been asso-
ciated with any of the following events: QT/QTc
prolongation, TdP or sudden death during postmarketing
surveillance.
The "thorough QT/QTc study" – General Considerations
The "thorough QT/QTc study" is about to emerge as the
comprehensive "clinical data set" fully complying with
current regulatory requirements, as opposed to "non-clin-
ical" testing that may, or may not generate sufficient infor-
mation considered to preclude risk of QT/QTc
prolongation. Judgement is required on a case-to-case
basis on whether the "clinical data set" following com-
pleted non-clinical testing [32,33] is still necessary or not,
with correspondent adjustment of study design variables.
Being considered a biomarker of proarrhythmic risk, the
QT/QTc interval is the pharmacodynamic (PD) parameter
which is explored to assess drug induced changes in heart
rate (HR) and ECG parameters as correlated to plasma
drug concentrations (PK). The PK/PD analysis implies a
standardized collection of blood samples for determina-
tion of PK parameters (Cmax, Tmax, AUC) and recording
of 12-lead ECGs for measurement and computation of
specific ECG parameters (PR, QRS, QT/QTc). All of these
measurements can be expected to show exposure-
response relationships that enhance comparison of the
investigated drug with its comparator (placebo or active),
primarily with respect to its safety.
In early phase I studies, when the PK profile of the drug is
eventually still unknown, a traditional PK study should be
performed with the aim to determine the plasma concentra-
tion-time profiles (see Fig. 2B). This allows not only calcu-
lation of AUC but also determination of concentration
"Humps" on the terminal part of the T-wave reflecting early  ADPs Figure 1A
"Humps" on the terminal part of the T-wave reflecting early 
ADPs. Figure 1b EAD degenerating in tachycardia.Current Controlled Trials in Cardiovascular Medicine 2005, 6:1 http://cvm.controlled-trials.com/content/6/1/1
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versus time profiles over a dosing interval for each indi-
vidual, as well as for the population. This approach yields
relatively detailed exposure information that can be corre-
lated to the observed responses in individuals. The expo-
sure-response relationship based on concentration-time
profiles can provide time-dependent information that
cannot be derived from AUC or Cmin.
Within the bounds of maintained safety and tolerability,
the QT/QTc evaluation should also be performed on
ECGs recorded at substantial multiples of the maximum
therapeutic exposure (multiples of Tmax – see Fig. 2B –
samplings at 8, 12, 16, 20 and 24 hours from Tmax).
Knowledge of "concentration increases" that might occur
due to drug-drug or drug-food interactions require specif-
ically adjusted study designs. Likewise, in instances where
increased plasma concentrations and ensuing QT/QTc
prolongation effects may occur due to a metabolite with
different pharmacokinetic profile from that of the parent
drug (see Fig. 3A and 3B), a tailored study design will be
needed.
When the "through QT/QTc study" assessment is
intended to be performed in drugs with well known phar-
macokinetic profile (known optimal dose and therapeutic
window), the sampling plan for both blood collection
and ECG recordings will be spaced to match the known
peak plasma concentration (Cmax – for single doses of
the formulations) or the attained "steady state" after mul-
tiple dosing. Importantly, there can be large interindivid-
ual variability in the time to peak concentration with
differences in the PK profile (e.g., Tmax, time to Cmax)
due to demographics, disease states, etc., compelling to
closely spaced samplings to account for these differences.
Study design – Methodological Considerations
The study design needs to be adjusted to the individual
drug's pharmacokinetics and safety characteristics. Both
the crossover and the parallel designs have specific advan-
tages and relative disadvantages that need to be taken into
account in the particular case at hand (see Additional file
1). However, as a rule, regardless of the design alternative
chosen, the study should be randomised, double-blind and
controlled.
12-lead ECG sampling pattern in the run-in period (baseline) Figure 2A
12-lead ECG sampling pattern in the run-in period (baseline). Minimum number of recordings are highlighted at 8, 14 and 20 
hours. Figure 2B Plasma concentration-time profiles (PK/PD analysis).
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Primary objectives
To quantify the dose-, concentration-, and time-relation-
ships of the drug on the QT/QTc interval in the target pop-
ulation at therapeutic and supra-therapeutic plasma
concentrations.
Secondary objectives
Collection of (serious) adverse events such as:
• Absolute QT/QTc prolongation: - QTc > 500 ms and/or
- QTc > 60 ms increase as compared to baseline
• Events suggestive of arrhythmia:- TdP
- Cardiac arrest/Sudden death
- VT/VF
- Syncope
- Dizziness
- Seizures
- Palpitations
Selection of control
Selecting a control for the purpose of demonstrating
safety of a product in terms of "no risk for QT/QTc prolon-
gation effect" is inevitably facing the question of whether
an active control or a placebo should be used. The basic
assumption is however, that the largest time-matched
mean (baseline subtracted) difference between the drug
and control (placebo or active control) for the QT interval
is ≤ 5 ms, with a one-sided 95% CI that excludes an effect
at <8 ms.
Placebo-controlled trials are still used to demonstrate
effectiveness of new drugs and, for circumstance in which
no increased risk for patients is foreseen, use of placebo
seems appropriate and ethical, provided that the patients
are fully informed and that they give written, informed
consent [34-36].
At closer scrutiny, use of placebo in the particular case of
demonstrating safety of a drug is not, by far, so much eth-
ically charged as usually, as the subjects supposed to
receive it are, in fact, exposed to a lesser degree of risk by
QT prolongation. On the other hand, the "placebo-
induced changes" are a reflection of underlying variability
of the QT/QTc, an otherwise a well-known phenomenon.
With other words, use of placebo-control in these cases is
fully justifiable.
Use of an active control, while extensively advocated cur-
rently, due to its considerable credibility as compared
with placebo, may raise troublesome methodological
issues, typical for equivalence trials, such as the rigorous
choice of control agent with special emphasis to essay sen-
sitivity, etc.[34]. Commonly, the primary objective of an
equivalence/noninferiority trial is to demonstrate that the
efficacy of a new treatment matches that of the control
treatment while, in the "thorough QT/QTc study", the
Plasma concentration-time profile of parent drug Figure 3A
Plasma concentration-time profile of parent drug. Figure 3B Plasma concentration-time profile of metabolite.
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goal is to demonstrate that the safety of the new drug is
equal or at least not worse than that of the control agent.
This translates into the need to demonstrate that the new
agent doest not prolong the QT/QTc by more than 5 ms
on average, as compared to the control. That is to say that
the "equivalence margin" is set to 5 ms, although, a defi-
nite prolongation effect will be stated if the upper bound
of the one-sided 95% CI would exceed 8 ms [5].
The 5 ms value, as an average threshold for demonstrating
non-inferiority of the tested drug versus a comparator,
might be a too ambitious cut-off point (i.e., too low).
With the technique currently available, this level of accu-
racy may possibly be attained by some highly skilled ana-
lysts, but it might be difficult to be maintained as an
average level for an entire group of analysts. A more rea-
sonable and practically attainable average value would be
10 ms. Individual subjects displaying prolongation in
excess of 10 ms would, however, need to be given careful
scrutiny.
Target patient population
These studies are generally performed in normal, healthy,
adult volunteers. The subject population should be
selected carefully to minimize inter-subjects variations.
Restrictive eligibility criteria are recommended in early
phase studies (I and II) of compounds known to have
APD or QT prolonging effects, with subsequent widening
of criteria in later phase studies (II and III).
It is estimated that ECGs should be generated in at least
100 volunteers (including females and males), for NCE
with no pre-clinical evidence of QT prolongation [37],
and in at least 200 volunteers (including females and
males) for NCE with pre-clinical evidence of prolonged
action potential duration or prolonged QT/QTc [37].
The test and the reference products are usually adminis-
tered to the subjects in the fasting state (overnight fast for
at least 10 hours). These subjects should not take any
other medication for one week prior to the study or during
the study. Identical test conditions must be used for the
two group subjects with respect to: foods, fluid intake,
physical activity, posture, etc. and, the physical character-
istics of the subjects should be standardized (age, height,
weight, and health) [38].
Clinical studies in later phases of development (phase III)
and after market approval (phase IV) are supposed to have
enlarged inclusion criteria to encompass female and eld-
erly patients, patients with associated comorbidities and
with concomitant treatment. Exposure to the relative new
treatment of a heterogeneous population, to mimic the
real population anticipated to be the end-user of the drug
in the future, is meant to create a "worst case scenario" for
drugs that in the pre-clinical and clinical development
stages have shown effects on the QT/QTc interval. Estab-
lishing with confidence the behaviour of the QT/QTc
interval in these patients, while exposed to the peak effect
(Cmax/steady state) of the drug, is not only an effective
risk management tool but also a highly ethical issue.
Timing of ECG recordings
Baseline ECG sampling
For NCE with suspected, or known from previous clinical
studies, effects on the HR and/or APD, 10 to 20 baseline
ECGs are required (see Fig. 2A). For agents administered
intermittently, repeated baseline ECG assessments may be
needed prior to each new treatment period. Carry-over
effects should be carefully taken into consideration when
cross-over design is employed.
During the run-in period of later phase trials (II-III), at
least three baseline ECGs should be recorded [39].
"On-treatment" ECG sampling
The pattern of ECG sampling should match the planned
blood sample collections for PK assessment (see Fig. 2B).
There will be a few or up to 20 ECGs recorded during 24
hours period, depending on how the PK/PD analysis has
been planned to be performed, on the amount of knowl-
edge regarding the agent's pharmacokinetics as well as on
the information generated by previous pre-clinical
studies.
However, regardless of the study design, whenever possi-
ble, ECGs should be recorded at the same time of the day
during both baseline period and after randomisation
(during "on-treatment") to minimize the confounding
effects of diurnal variations and postprandial effects [37].
For drugs with known metabolite(s), the ECG recordings
should cover the prolonged blood sampling for the
plasma concentration-time profile of the metabolite (see
Fig. 3B).
Whenever ethically justifiable, for the case of inadvertent
over-dosage or metabolic inhibition, it is recommendable
that ECGs should be recorded at substantial multiples of
the maximum therapeutic exposure, even in excess of the
upper bound of the anticipated therapeutic range (see Fig.
2B – sampling at 28 hours).
Measurement of QT interval
Quality of ECG recordings is of paramount importance
for the reliability of the data generated. Poor quality traces
due to artefacts or lead misplacement should be avoided
through appropriate training of the staff in charge with
acquisition of ECGs. Whether these people areCurrent Controlled Trials in Cardiovascular Medicine 2005, 6:1 http://cvm.controlled-trials.com/content/6/1/1
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professionals or temporary research staff, all are supposed
to have a high level of expertise in ECG acquisition tech-
nique and be able to validate tracings that are analysable
or not.
Standard 12-lead ECGs should be taken in supine, after at
least 5 minutes rest with default calibration of the record-
ing device at 1 mV, speed at 50 mm/s.
Currently, standard lead II is chosen for measurement of
RR and PR interval, QRS complex and the QT interval, on
at least three cardiac cycles. Two additional precordial
leads may be used for performance of the same measure-
ments (e.g., V3-V4). Means are computed consequently,
from one or three leads.
Manual measurement of different ECG parameters is
charged with problems of accuracy and reproducibility
due to the inter- and intra-observer variability inherent in
such highly demanding tasks while, interpretation of ECG
tracings is known to vary from one clinician to another
[40].
However, ICH-GCP-compliant quality control and qual-
ity assurance SOPs, as well as systematic performance
analyses applied to the individual analysts/technicians
and their output data, employed nowadays in certain core
laboratories, ensure the prospective clients of minimized
inter- and intra-observer variability regarding the meas-
urements performed and of high level of accuracy of the
output results in the range of ± 10 ms, around a selected/
agreed "gold standard" [41].
In order to ensure an overall high level of performance
within a group of technicians/analysts who perform the
factual measurements on ECG tracings, performance anal-
ysis applied to the group and each individual member of
the group, should be run at six months interval. Deviation
in the measurements performed of more than ± 10 ms
should be addressed speedily and corrective measures
implemented. Such quality-assurance performance analy-
ses may maintain a high level of measurements' homoge-
neity and ensure a high quality of the data provided.
Likewise, ECG tracings as well as summary data are sub-
ject to interpretation and reporting by qualified cardiolo-
gist(s) [4].
Fig. 4 depicts a normal ECG with the most common
parameters measured in the process of exploring any new
NCE's effects on the QT/QTc interval. Apparently, measur-
ing the QT interval should be a quite straightforward task,
however, in practice there are a number of pitfalls and dif-
ficulties [30,31].
The beginning of the QRS complex is best determined in
a lead with an initial "q" wave – commonly standard lead
I or II, and leads aVL, V5 and V6. Sometimes, the "q" wave
may be missing (the initial part of the QRS complex is iso-
electric) due to its incorporation within the PR interval.
Determining the precise end of the T wave may be simple,
when a tangent line to the steepest part of the descending
portion of the T wave is drawn and the intercept between
the tangent and the isoelectric line is indicating the end of
T wave. At times, however, the T wave may be obscured by
a superimposed U wave or, in the case of sinus tachycar-
dia, by the ensuing P wave, making the positioning of the
fiducial point difficult.
The U wave deflection is usually minimal or isoelectic in
lead aVL. The aVL lead is therefore a useful for QT meas-
urement since the end of the T wave is least likely to be
obscured by a U wave.
TU morphology assessment
Different repolarization properties among the epicar-
dium, M cells, and endocardium, as well as their interplay,
are responsible for various morphologies of the T-wave
and the pathologic U-waves. The T-wave is a symbol of the
transmural dispersion of repolarization.
Several hypotheses have been proposed to explain the
genesis of the U-wave, which represents the last repolari-
zation component of the ventricules [42] however, the
hypothesis that the Purkinje network is responsible for
the physiologic U-wave seems most plausible.
Morphology changes of the T and U-wave should be inter-
preted as warning signs of TdP. Sometimes, a clear demar-
cation between the two waves is very difficult, exposing to
the risk of underestimating the QT interval and, ulti-
mately, to missing the clinical significance of the changes
per se. Clearly, both qualitative and quantitative assess-
ments of the repolarization changes occurring with differ-
ent degrees of merger between the T and the U-wave are
subject to a certain degree of subjectivity of the assessor.
Therefore, it is recommendable that TU-wave morphology
assessment to be made by qualified cardiologist(s)
according to a standardised methodology. Additional file
2 captures the possible changes that may be encountered
in the T-waves, U-waves and different forms of TU mergers
in a particular individual. Additional file 3 summarizes
the frequency distribution of TU morphology changes
across two groups compared.
Given the high level of subjectivity inherent in this type of
assessments, with considerable discrepancies between
two assessors, even when identical data are assessed, an
overall, reasonable conclusion on the TU morphologyCurrent Controlled Trials in Cardiovascular Medicine 2005, 6:1 http://cvm.controlled-trials.com/content/6/1/1
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changes can be provided by use of a visual analogue scale
(see Fig. 5). The degree of normality/abnormality in a par-
ticular case is estimated on a scale from 1 to 10, on which:
"1" – is definite abnormal and "10" – is unquestionably
normal. As an example, the flat-to-small negative T-waves
in V5/V6 in the early phase of hypertension could be
scaled as "7", whereas the large negative T-waves in the
same leads, in the case of severe aortic stenosis, would be
scaled as "1". A classical "borderline" change would be
given a "5".
QT dispersion (QTD)
Increased dispersion on the QT interval of the electrocar-
diogram has been proposed as a marker for increased risk
of arrhythmias in patients with hypertrophic cardiomyop-
athy [48], long QT intervals [44], and sustained
Normal ECG highlighting the common parameters measured when assessing the QT/QTc interval Figure 4
Normal ECG highlighting the common parameters measured when assessing the QT/QTc interval.
Tasc.                                          Tdesc.
Q
P
ST
Segment
QT Interval
S
PR
Segment
PR Interval
R
QRS Complex
TPeak TEnd
U
Tpe IntervalCurrent Controlled Trials in Cardiovascular Medicine 2005, 6:1 http://cvm.controlled-trials.com/content/6/1/1
Page 9 of 13
(page number not for citation purposes)
ventricular arrhythmias [45]. Most of the studies explor-
ing QT dispersion were small and, thereby could not pro-
vide accurate data for the sensitivity and specificity of the
method to be derived. One study has assessed different
cut-off values for QT dispersion by employing ROC
analysis, however, the QT dispersion analysed was essen-
tially developed on the basis of a training set [46]. The
average normal value of QT dispersion in normal subjects
was ≤ 40 ms in 13 studies and ≥ 40 ms in eight studies
[47]. The Rotterdam study reported QTc dispersion > 60
ms in apparently healthy subjects aged ≥ 55 years in
whom a two-fold increase in sudden death was registered
subsequently [48].
Despite sophisticated methods of computerised measure-
ments of QT dispersion [49,50], the reliability of both
manual and automatic measurement of QT dispersion is
low and the method is considered a crude measure of the
abnormalities during the whole course of repolarization
[51]. However, more recent studies [52,53] indicated that
dispersion in repolarization may arise from differences in
the action potential durations between cells situated in
difference myocardial layers and that heterogeneity in
repolarization might be linked to induction of ventricular
fibrillation [42].
The analysis of repolarization variability is commonly
based on methods that evaluate spatial and temporal QT
dispersion. Recent experimental studies [54] in arterially
perfused canine left ventricular wedge preparations, sug-
gest that the second part of the T wave represents the
arrhythmogenic substrate and that the peak-to-end inter-
val of the T wave is the trasmural dispersion of the repo-
larization. The TPE interval of the T wave is postulated to
reflect the transmural dispersion in humans (as measured
in V5) and might become a parameter to be routinely
measured in the future. It is claimed that TPE correlates
better than the QT-dispersion with TdP and that a TPE >
280 msec may be useful in predicting risk of TdP in
acquired LQTS.
Heart rate correction of QT interval
The length of the QT interval varies inversely with heart
rate and therefore shortens as the heart rate increases. Due
to the known substantial inter-subject variability of the
QT/RR interval relation, there is no mathematical formula
to fit every individual. A formula that performs well in
one healthy individual may not do so in another, result-
ing in over- or undercorrection of the QT interval.
Several correction formulas exist. The Bazett formula
(square root – QTcB = QT/RR1/2) [55,56], most com-
monly used, is known to overcorrect at high heart rates
and undercorrect at low heart rates [57,58]. The Fridericia
formula (cubic root – QTcF = QT/RR1/3) [59] is considered
to reflect a more accurate correction factor in subjects with
tachycardia.
A more recent formula is the Framingham linear correc-
tion (QTcL = QT + 0.154 × [1 - RR]) known to be derived
from a large patient population and thereby to be
considered the most rigorous from an epidemiological
perspective [60,61].
The main limitation in the aforementioned formulas is
that each of them attempts to correct for heart rate only,
Visual Anlogues Scale to assist in reconciliating the inter-observer assessment of TU morphology Figure 5
Visual Anlogues Scale to assist in reconciliating the inter-observer assessment of TU morphology.
1  2                   3                  4        5  6                   7                  8        9                 10
1 - Abnormal
5 - Borderline
10 - Unquestionably normal
Ex. The flat-to-small negative T waves in V5/V6 in the early phase of hypertension could be scaled as “7”, whereas
the large negative T waves in the same leads, in the case of severe aortic stenosis would be scaled as “1”. A
classical “borderline” change would be assigned a “5”.Current Controlled Trials in Cardiovascular Medicine 2005, 6:1 http://cvm.controlled-trials.com/content/6/1/1
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while leaving into play a number of other known con-
founders (diurnal variability, effect of physical exercise,
etc.). Disappointingly, analysis done on ECGs sampled
from periods of stable heart rate provided no better results
[62]. According to Malik et al., the relation between QT
interval and heart rate is highly individual [63]. Using a
parabolic heart rate correction formula (QTc = QT/RRα)
they demonstrated a large variability of the α exponent
(range: 0.233 – 0.485) in 50 healthy subjects. The same
parameter in Fridericia's and Bazett's formulas is 0.33 and
0.50 respectively. Malik and colleagues concluded that
correction of QT interval by heart rate may be misleading,
regardless of the method used.
QT/RR regression models [64,65] can be used for comput-
ing the "right formula for the right data" in experimental
situation, however, for practical purposes the Bazett and
Fridericia as well as the linear corrections are preferred at
present (from regulatory point of view).
Reporting of measurement results
Reporting of results becomes mostly informative if tabular
frequency distribution and frequency histograms are used
to display PR, QRS and QTc data (QTcB, QTcF, QTcL) for
individuals and/or groups. For the hypothetic example
captured in Fig. 2B, tabular representation of the data
might be used to illustrate the frequency distribution of a
number of parameters (PR, QRS, QTcB, QTcF, QTcL)
matching the PK sampling (see Additional file 4). Sum-
mary data for the same parameters (Min, Max, Mean) as
compared to baseline can be displayed for individual sub-
jects and/or group of subjects (see Additional file 5). The
relevant normal ranges for all parameters are given in
Additional file 6.
Additional file 7 captures the baseline,  mean  and  mean
maximum values for all parameters measured/computed
for one group (PR, QRS, QT, QTcB, QTcF and QTcL) and
displays the difference (D1) between the mean value of
each parameter "on-treatment" and the corresponding
mean value at baseline. Given that a D2 value is to be com-
puted for the second group (comparator), their difference
(D2 – D1), for all parameters and the resulting p value
(Bomferoni adjusted) could be displayed in Additional
file 8.
Risk assessment as related to prolonged QT/
QTc interval
Risk-benefit assessment with respect to a drug's propen-
sity to prolong the QT/QTc interval entails a careful judge-
ment of the frequency and magnitude of QT changes
encountered in the preclinical and/or clinical program
and balancing the potential risks against the drug's
benefit.
The large variability in the prolonged QT/QTc behaviour
as to the potential risk for a TdP ensuing, makes this task
difficult and requires individual characterisation of a spe-
cific drug's effects on repolarization.
Amiodarone, for example, is known to prolong repolari-
zation but to cause rarely TdP. Sotalol which prolongs
repolarization through the same mechanism of action as
Amiodarone (blockade of the IKr channel) causes a more
frequent occurrence of TdP [66].
Some agents may cause slight QTc prolongation but when
combined with other drugs that inhibit the metabolism of
the suspected drug (e.g., terfenadine and cisapride),
marked prolongation can occur [67]. A typical example is
dofetilide, a potent QT-prolonging class III antiarrhyth-
mic agent indicated for atrial fibrillation. Concomitant
administration of cimetidine with dofetilide was shown
to enhance the QT-prolonging effect resulting in a dose-
dependent, baseline-related QTc increase of 22% and
33% with 100 mg and 400 mg of cimetidine respectively
[68].
It is estimated that about 40–50% of the cases of drug-
induced QT interval prolongation and/or TdP, result from
drug-drug interactions with metabolic inhibitors (as in
the example of dofetilide-cimetidine) and that only 10%
are associated with electrolyte imbalance, some 10% with
concurrent use of other QT-prolonging drugs and approx-
imately 10–20% of cases have no obvious risk factors
[69].
As a general rule, it is recommended that any prolonga-
tion should be considered as a potential toxicity [36]. In
this context, it has become a widespread consensus that
outliers with QTc > 500 ms or a baseline-related increase
of QTc > 60 ms are better predictors than the mean QTc
values [44]. In such instances, a careful screening for asso-
ciated underlying risk factors or concomitant drugs is rec-
ommended, in order to determine the best course of
action. Small QT prolongations (<10 ms) are acceptable
as long as there are no associated risk factors. Longer QTc,
however, requires individual monitoring and withdrawal
from study should be considered, while further elective
investigation should be scheduled on a case-to-case basis
(see Additional file 9).
Risk management for marketed products
Ideally, therapy should be individualized on the basis of
patient's genotype/phenotype determined through
pharmacogenetic studies performed in the early stages of
a drug's development and through application of that
information while exploring the drug's pharmacokinetic
and pharmacodynamic properties, its drug interactionCurrent Controlled Trials in Cardiovascular Medicine 2005, 6:1 http://cvm.controlled-trials.com/content/6/1/1
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potential as well as when ethnical-based bridging data is
generated.
While genotyping of individual cases, where prior
informed consent is obtained, based on strong suspicion
of genetic substrate having caused substantial QT/QTc
prolongation is highly recommendable (such as, outliers
in phase I-III studies, patients withdrawn from study due
to lack of efficacy or due to type A adverse events), large-
scale genotyping in early stages of drug development or
pre-prescription genotyping are still controversial.
Consequently, the clinical and scientific community is
facing the need to apply classical "individualizing ther-
apy" approaches [70] in reducing the clinical risk of QT/
QTc-related adverse events (TdP, VT/VF, sudden death,
etc.).
Obviously, the most elementary requirement in this
respect is that prescribing physicians should fully comply
with contraindications regarding co-prescription of inter-
acting drugs and with the recommendation on appropri-
ate monitoring of targeted patients. More specifically,
attention should be given to pharmacokinetic and
pharmacodynamic factors that constitute important risk
factors [4].
Liver and/or renal diseases act as risk factors at pharma-
cokinetic level. Likewise, a multitude of metabolic inhibi-
tors (see Additional file 10), when temporarily co-
administered, develop high plasma concentration of the
parent drugs, exposing them to high-dose pharmacology
of the drugs concerned [4].
Pharmacodynamic risk factors include diseases that are
associated with QT interval prolongation (see Additional
file 11).
Obviously, appropriate monitoring is a sine qua non con-
dition for preventing SAE in patients known to be treated
with QT-prolonging drugs. QT interval should be moni-
tored in these patients: (i) at baseline; (ii) at steady-state
post-dose and at each incremental dose; (iii) when there
is an inter-current change in level of risk, and (iv) if the
patient develops symptoms of tachycardia or impaired
cerebral circulation [4]. Treatment should be discontin-
ued if QTc ≥ 500 ms and appropriate measures instituted
based on the clinical picture at hand.
Occurrence of typical AE suggestive of eventual QT-pro-
longation, should prompt careful investigation of this
possibility even in cases where initial QT/QTc assessment
has shown to be negative. In such instances, it is recom-
mended that screening for risk factors shall be employed
and genotyping performed after receipt of informed con-
sent. Furthermore, consideration should be give to "re-
challenge" with the investigational drug under appropri-
ate monitoring conditions, with the aim of obtaining an
accurate assessment of the situation at hand as well as for
getting useful information on dose- and concentration-
response relationship.
Conclusions
Compelling evidence has accrued during the past years on
the potential of several cardiac and non-cardiac drugs to
prolong cardiac repolarization (reflected as prolonged QT
on surface ECG) and to predispose to life-threatening
arrhythmias.
This evidence has a major impact on the risk-benefit ratio
of any drug, currently carefully considered from early
stages of clinical drug development by pharmaceutical
companies, by ethics committees as well as by regulatory
agencies.
The broad spectrum of risk factors that may interplay in
the increased propensity toward malignant arrhythmias
of any new chemical entity is just increasing (congenital
LQTS, genetic substrate, comorbidities, concomitant treat-
ment) and adding to the complexity of the problem.
This calls for standardized methodologies to deal with the
multifaceted aspects that the QT/QTc prolongation poses
in practice, meant to ensure that drugs awarded market
approval have undergone appropriate quality assurance
scrutiny and, where necessary, further post-marketing sur-
veillance is systematically planned and reported on, in a
timely manner.
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